Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis.
暂无分享,去创建一个
S. Rizzo | G. Thiene | C. Basso | C. Campochiaro | S. Sartorelli | G. de Luca | L. Dagna | C. Selmi | A. Palmisano | P. Della Bella | A. Esposito | S. Sala | E. Gremese | M. De Santis | G. Peretto | S. Bosello | G. Canestrari | E. De Lorenzis
[1] C. Campochiaro,et al. Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis , 2019, Annals of the Rheumatic Diseases.
[2] H. Dalen,et al. Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications , 2019, ACR open rheumatology.
[3] M. Nurmohamed,et al. Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. , 2019, Autoimmunity reviews.
[4] S. Rizzo,et al. Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. , 2019, International journal of cardiology.
[5] G. Thiene,et al. Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome , 2019, Scandinavian journal of rheumatology.
[6] G. de Luca,et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. , 2019, European journal of internal medicine.
[7] C. Campochiaro,et al. Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report , 2018, Scandinavian journal of rheumatology.
[8] S. Rizzo,et al. Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. , 2019, Journal of autoimmunity.
[9] A. Tomelleri,et al. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. , 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[10] C. Campochiaro,et al. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. , 2018, Annals of internal medicine.
[11] C. Campochiaro,et al. Myocarditis: An Interleukin-1-Mediated Disease? , 2018, Front. Immunol..
[12] A. Tomelleri,et al. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease , 2018, Front. Immunol..
[13] D. Gladman,et al. Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies , 2018, Lupus.
[14] J. Lima,et al. Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. , 2018, International journal of cardiology.
[15] F. Crea,et al. Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst , 2017, Scandinavian journal of rheumatology.
[16] F. Crea,et al. Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome , 2016, PloS one.
[17] Andrea Mazzanti,et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.
[18] G. Lippi,et al. Troponin in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.
[19] P. Cluzel,et al. Myocarditis in Patients With Antisynthetase Syndrome , 2015, Medicine.
[20] U. Kramer,et al. Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy , 2015, PloS one.
[21] P. Matthews,et al. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping. , 2015, JACC. Cardiovascular imaging.
[22] Zhilin Qu,et al. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. , 2014, Journal of molecular and cellular cardiology.
[23] F. Crea,et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. , 2014, Seminars in arthritis and rheumatism.
[24] S. Kaptoge,et al. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. , 2013, The American journal of cardiology.
[25] Stefan Neubauer,et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. , 2013, JACC. Cardiovascular imaging.
[26] A. Angelini,et al. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease , 2013, Heart Failure Reviews.
[27] A. Angelini,et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. , 2012, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[28] P. MacEneaney,et al. Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone , 2010, Scandinavian journal of rheumatology.
[29] E. Feierl,et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.
[30] D. Farge,et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.
[31] G. Kolovou,et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. , 2009, Inflammation & allergy drug targets.
[32] Andrea Frustaci,et al. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.
[33] Matthias Gutberlet,et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .
[34] D. Corrado,et al. Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. , 2008, European heart journal.
[35] H. Champion. The heart in scleroderma. , 2008, Rheumatic diseases clinics of North America.
[36] J. Ornato,et al. [ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. , 2006, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[37] Dan M. Roden,et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .
[38] K. Resch,et al. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. , 2001, Scandinavian journal of rheumatology.
[39] B. Boland,et al. Intravascular haemolysis in hypertrophic cardiomyopathy. , 1996, European heart journal.
[40] B Maisch,et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.
[41] W. Edwards,et al. Myocarditis. A histopathologic definition and classification. , 1987, The American journal of cardiovascular pathology.
[42] G. Hutchins,et al. Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.
[43] E. F. Doyle,et al. Major Changes Made by Criteria Committee of the New York Heart Association , 1974, Circulation.